Literature DB >> 16020951

Detoxifying capacity and kinetics of prometheus--a new extracorporeal system for the treatment of liver failure.

Pieter Evenepoel1, Wim Laleman, Alexander Wilmer, Kathleen Claes, Bart Maes, Dirk Kuypers, Bert Bammens, Frederik Nevens, Yves Vanrenterghem.   

Abstract

BACKGROUND/AIMS: Extracorporeal liver support therapies have been used for several decades as a bridging therapy prior to liver transplantation or as an addendum to standard medical therapy. The Prometheus system represents a cell-free, extracorporeal, liver assist method for the removal of both albumin-bound and water-soluble endogenous toxins. The aim of the present study was to evaluate the removal capacity and selectivity of the different inbuilt dialyzers and adsorption columns during a single 6-hour treatment.
METHODS: Nine patients with acute on chronic liver failure were included (6 females, age 49+/- 4 years). Levels of endogenous toxins (urea nitrogen [UN, mg/dl], creatinine [Cr, mg/dl], total bilirubin [tB, mg/dl], and bile acids [BA, mumol/l]) and albumin [Alb, g/l] were monitored in blood sampled at different sites (arterial line, venous line and between the absorbers and the high-flux dialyzer) and at various time points (time 0, 30, 60, 120, 240, and 360 min).
RESULTS: A significant decrease of the serum level of all toxins was observed (UN 108.7+/- 23.2 vs. 38.1+/- 14.9, Cr 2.4+/- 0.7 vs. 1.2+/- 0.3, tB 31.1+/- 4.1 vs. 17.0+/- 1.6, BA 155.7+/- 32.5 vs. 66.0+/- 15.4; mean+/- SEM, time 0 vs. time 360, signed rank rest, all p< 0.005). The reduction rate of UN, Cr, tB and BA amounted to 68.1+/- 5.1, 45.9+/- 6.2, 41.2+/- 5.1, and 58.2+/- 5.0%, respectively. Blood clearances [Cl, ml/min] of all, but especially of the protein-bound toxins declined over time (Cl UN 171.5+/- 4.3 vs. 142.9+/- 16.8; Cl Cr 135.7+/- 10.0 vs. 111.8+/- 9.1; Cl tB 29.3+/- 5.1 vs. 13.7+/- 3.7; Cl BA 84.9+/- 4.8 vs. 45.1+/- 13.3; time 30 vs. time 360; linear mixed models, all p< 0.005). Serum albumin levels decreased by 2.9+/- 0.9 g/l (signed rank test, p=0.055). Not unexpectedly, tB was almost uniquely cleared by the adsorbers (UN 0.2+/-1.1, Cr 6.9+/- 5.7, tB 92.3+/- 4.2, BA 62.9+/- 3.9% of total Cl).
CONCLUSION: Both albumin-bound and water-soluble toxins are adequately removed by the Prometheus system. Our data suggest that the rate and efficacy of removal of albumin-bound toxins is related to both the strength of the albumin binding and the saturation of the adsorption columns. Limited losses of albumin occur during treatment with the Prometheus system. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020951     DOI: 10.1159/000086885

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  11 in total

1.  Artificial and bioartificial liver support.

Authors:  Gesine Pless
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

Review 2.  Liver support systems: will they ever reach prime time?

Authors:  Rafael Bañares; María-Vega Catalina; Javier Vaquero
Journal:  Curr Gastroenterol Rep       Date:  2013-03

3.  Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.

Authors:  Yang Zhang; Xiao-Yu Hu; Sen Zhong; Fang Yang; Tao-You Zhou; Guo Chen; Yan-Yan Wang; Jian-Xing Luo
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Thermodynamic considerations in solid adsorption of bound solutes for patient support in liver failure.

Authors:  John F Patzer
Journal:  Artif Organs       Date:  2008-07       Impact factor: 3.094

5.  MARS therapy, the bridging to liver retransplantation - Three cases from the Hungarian liver transplant program.

Authors:  Balázs Pőcze; János Fazakas; Gergely Zádori; Dénes Görög; László Kóbori; Eszter Dabasi; Tamás Mándli; László Piros; Anikó Smudla; Tamás Szabó; Eva Toronyi; Szabolcs Tóth; Gellért Tőzsér; Gyula Végső; Attila Doros; Balázs Nemes
Journal:  Interv Med Appl Sci       Date:  2013-07-04

6.  Present and Future Developments in Hepatic Tissue Engineering for Liver Support Systems : State of the art and future developments of hepatic cell culture techniques for the use in liver support systems.

Authors:  Sonja Diekmann; Augustinus Bader; Stephanie Schmitmeier
Journal:  Cytotechnology       Date:  2006-06-23       Impact factor: 2.058

7.  Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure.

Authors:  Vanessa Stadlbauer; Peter Krisper; Reingard Aigner; Bernd Haditsch; Aleksandra Jung; Carolin Lackner; Rudolf E Stauber
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

8.  An evaluation of the usefulness of extracorporeal liver support techniques in patients with severe liver dysfunction.

Authors:  Mariusz Piechota; Anna Piechota; Małgorzata Misztal; Szymon Bernas; Iwona Pietraszek-Grzywaczewska
Journal:  Arch Med Sci       Date:  2017-05-25       Impact factor: 3.318

9.  Evaluation of the Hepa Wash® treatment in pigs with acute liver failure.

Authors:  Ahmed Al-Chalabi; Edouard Matevossian; Anne-K V Thaden; Peter Luppa; Albrecht Neiss; Tibor Schuster; Zejian Yang; Catherine Schreiber; Patrick Schimmel; Ewald Nairz; Aurel Perren; Peter Radermacher; Wolfgang Huber; Roland M Schmid; Bernhard Kreymann
Journal:  BMC Gastroenterol       Date:  2013-05-13       Impact factor: 3.067

10.  Evaluation of an ADVanced Organ Support (ADVOS) system in a two-hit porcine model of liver failure plus endotoxemia.

Authors:  Ahmed Al-Chalabi; Edouard Matevossian; Anne von Thaden; Catherine Schreiber; Peter Radermacher; Wolfgang Huber; Aritz Perez Ruiz de Garibay; Bernhard Kreymann
Journal:  Intensive Care Med Exp       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.